RAMAIAH ISSN (Print) : 0975-7988

MS RAMAIAH MANAGEMENT REVIEW
July - September 2025, Vol 16(03), 68 – 76
DOI: 10.52184/msrmr.v16i03.121

Enhancing Environmental Sustainability and Operational Performance in Pharmaceutical Manufacturing: The Role of Technology Adoption

Noraini Ismail

Pharmaniaga Berhad, Seksyen, Selangor

Mohd Fathi Abu Yaziz

Arshad Ayub Graduate Business School (AAGBS), Universiti Teknologi Mara, Selangor, Malaysia
noraini.ismail@pharmaniaga.com

Article Type: Research Article

Article Citation: Noraini Ismail and Mohd Fathi Abu Yaziz, Enhancing Environmental Sustainability and Operational Performance in Pharmaceutical Manufacturing: The Role of Technology Adoption. M.S. Ramaiah Management Review. 2025; 16(03), 68-76. DOI: 10.52184/msrmr.v16i03.121

Received date: October 30, 2024

Accepted date: December 30, 2024

***Author for correspondence:**
Mohd Fathi Abu Yaziz noraini.ismail@pharmaniaga.com Arshad Ayub Graduate Business School (AAGBS), Universiti Teknologi Mara, Selangor, Malaysia

Abstract

The pharmaceutical industry faces growing pressure to enhance environmental sustainability while adhering to strict regulatory and performance standards. This paper explores the role of technology adoption in enhancing both operational performance and environmental sustainability within pharmaceutical manufacturing. The study employs a qualitative research methodology involving a literature review to identify key trends, challenges, and best practices, emphasizing the importance of technology adoption and sustainability integration in pharmaceutical manufacturing. The findings highlight that digitalization, automation, and process optimization are critical in reducing waste, improving energy efficiency, and enhancing overall productivity. However, the successful implementation of these technologies depends on several factors, including organizational readiness and external pressure. This research contributes to the discourse on sustainable practices in pharmaceutical manufacturing, offering insights into bridging the gap between sustainability and performance. The paper provides valuable recommendations for practitioners, policymakers, and academics interested in enhancing both operational efficiency and environmental sustainability in the pharmaceutical industry.

Keywords: Environmental Sustainability, Operational Performance, Technology Adoption, Manufacturing, Pharmaceutical Industry.

1 Introduction

The pharmaceutical industry plays a critical role in public health, providing essential medications that improve quality of life and extend life expectancy. However, this industry is also a significant contributor to environmental degradation, primarily due to its complex manufacturing processes, which generate considerable waste, emissions, and resource consumption (Riikonen et al., 2024). As global awareness of environmental issues intensifies, stakeholders including governments, consumers, and investors are increasingly demanding that pharmaceutical companies adopt environmentally sustainable practices. This shift is not merely a response to regulatory pressures but also a recognition of the long-term benefits that sustainability can bring, including enhanced operational efficiency, reduced costs, and improved brand reputation (Emara et al., 2018).

Environmental sustainability in the pharmaceutical sector encompasses a wide range of practices aimed at minimizing ecological footprints throughout the product lifecycle, from research and development (R&D) to manufacturing, distribution, and disposal (Pesqueira & Sousa, 2020). The traditional manufacturing processes often result in significant waste and energy consumption, necessitating a shift towards more sustainable methodologies. Life Cycle Assessment (LCA) has emerged as a vital tool in evaluating the environmental impacts of pharmaceutical products throughout their life cycles, from raw material extraction to end-of-life disposal (Emara et al., 2018). However, the limited application of LCA in the pharmaceutical industry is attributed to challenges such as confidentiality and the low production volumes of active pharmaceutical ingredients (APIs) (Emara et al., 2018). This underscores the need for innovative approaches to enhance sustainability.

Digital transformation plays a crucial role in reshaping the pharmaceutical supply chain. Enhanced information sharing and traceability enabled by digital technologies can significantly improve sustainable supply chain performance (Ma et al., 2022). The integration of Industry 4.0 technologies, such as the Internet of Things (IoT) and artificial intelligence (AI), can facilitate real-time monitoring and optimization of manufacturing processes, thereby reducing waste and energy consumption (Debnath, 2023). Furthermore, the adoption of continuous manufacturing techniques can lead to more efficient production processes, aligning with sustainability goals (Raza, 2023).

Despite the potential benefits, the successful adoption of these technologies depends on several factors, including organizational readiness and regulatory compliance. Management support is identified as a critical success factor in implementing Industry 4.0 technologies within the pharmaceutical sector (Debnath, 2023). Additionally, fostering a culture of innovation and collaboration among stakeholders is essential for overcoming barriers to technology adoption and achieving sustainability objectives (Yang, 2023).

This paper aims to explore the role of technology adoption in enhancing environmental sustainability and operational performance in pharmaceutical manufacturing. It also examines the critical factors that influence technology adoption and offers recommendations for integrating sustainability into strategic decision-making processes. By bridging the gap between sustainability and performance, this paper contributes to the growing discourse on

sustainable industrial practices and provides valuable insights for practitioners, policymakers, and academics.

2 Literature Review and Development of Model

2.1 Operational Performance

Operational performance in pharmaceutical manufacturing encompasses efficiency, quality, compliance, and innovation within a highly regulated industry. Central to operational excellence are metrics that gauge resource utilization, productivity, and adherence to quality standards. The pharmaceutical sector faces unique operational challenges, such as stringent regulatory requirements, the complexity of manufacturing processes, and the need for rapid responsiveness to market demands (Riikonen et al., 2024). As competition intensifies and compliance costs rise, achieving operational efficiency has become a critical priority.

Process optimization, facilitated by Six Sigma and Lean Manufacturing methodologies, has bolstered operational performance. Research indicates that the implementation of lean manufacturing principles can significantly enhance operational efficiency by minimizing waste and optimizing resource utilization (Younnes, 2023). In the context of pharmaceutical manufacturing, lean practices can reduce production costs while simultaneously addressing environmental concerns. For instance, the adoption of automated systems can streamline production processes, leading to reduced cycle times and improved product quality (Raza, 2023).

The integration of continuous manufacturing processes represents another significant advancement in operational performance. Continuous manufacturing allows for the uninterrupted production of pharmaceuticals, which can lead to reduced production costs and improved product quality (Domokos et al., 2021). Studies have indicated that continuous processing can minimize waste and energy consumption compared to traditional batch processing, thereby aligning with sustainability goals (Domokos et al., 2021). However, the transition to continuous manufacturing requires substantial investment in technology and training, which can pose challenges for some organizations (Domokos et al., 2021).

Furthermore, the importance of regulatory compliance in enhancing operational performance cannot be overstated. Regulatory agencies impose stringent guidelines on pharmaceutical manufacturing to ensure product safety and efficacy. Compliance with these regulations is essential for maintaining operational performance and avoiding costly penalties (Ingale et al., 2023). Therefore, organizations must invest in robust quality management systems and employee training to ensure adherence to regulatory standards while optimizing operational processes (Ingale et al., 2023).

The integration of advanced technologies such as automation and digitalization has been shown to enhance operational performance in pharmaceutical manufacturing. Automation can streamline production processes, reduce human error, and improve product quality (Debaveye et al., 2018). Additionally, the integration of digital technologies into pharmaceutical supply chains has been shown to enhance traceability and information sharing, which are critical for achieving sustainability goals (Ma et al., 2022). The ability

to track products throughout the supply chain enables manufacturers to identify inefficiencies and implement corrective measures, thereby reducing waste and improving overall performance (Haji et al., 2021). Besides, the application of Industry 4.0 technologies can facilitate the transition towards more sustainable manufacturing processes by enabling real-time data analysis and decision-making (Arden et al., 2021).

Enhancing operational performance in pharmaceutical manufacturing involves process optimization, continuous manufacturing processes, compliance with regulatory requirements and integration of advanced technologies. These strategies not only improve efficiency and reduce costs but also contribute to the overall sustainability of the industry by minimizing waste and energy consumption.

2.2 Environmental Sustainability

Environmental sustainability in pharmaceutical manufacturing encompasses various dimensions, including waste reduction, energy efficiency, and responsible resource management. The pharmaceutical industry is known for its significant environmental footprint, primarily due to the high energy consumption and waste generation associated with traditional manufacturing processes (Tao et al., 2023). Therefore, adopting sustainable practices is not only a regulatory requirement but also a strategic imperative for enhancing operational performance.

One of the key strategies for improving environmental sustainability is the adoption of green manufacturing practices. Green manufacturing, which emphasizes the reduction of environmental impacts throughout the production process, has gained traction in the pharmaceutical sector (D'Angelo et al., 2022). This approach involves the use of environmentally friendly materials, energy-efficient technologies, and waste minimization techniques. For instance, enzymatic production processes have been shown to reduce waste generation and energy consumption compared to traditional methods (Grimaldi et al., 2021).

Moreover, the environmental sustainability of pharmaceutical manufacturing is often assessed through LCA, which evaluates the environmental impacts associated with all stages of a product's life cycle (Grimaldi et al., 2021). Studies have demonstrated that LCA can provide valuable insights into the environmental footprint of pharmaceutical products, guiding manufacturers in identifying areas for improvement (Riikonen et al., 2024). However, many LCAs in the pharmaceutical sector have focused predominantly on the production phase, often neglecting the environmental impacts associated with emissions and wastewater discharges (Emara et al., 2018). This highlights the need for a more comprehensive approach to assessing environmental sustainability in pharmaceutical manufacturing.

The implementation of circular economic principles is another avenue for promoting environmental sustainability in pharmaceutical manufacturing. By designing products for reuse and recycling, manufacturers can minimize waste and reduce their reliance on finite resources (Batista et al., 2023). This approach not only contributes to environmental sustainability but also offers economic benefits by reducing production costs and enhancing resource efficiency (Batista et al., 2023).

Furthermore, regulatory frameworks play a crucial role in promoting

environmental sustainability in the pharmaceutical sector. Stricter environmental regulations can incentivize manufacturers to adopt more sustainable practices, thereby improving their overall environmental performance and enhancing competitiveness in the market (Tao et al., 2023). Organizations must stay abreast of evolving regulations and invest in compliance measures to ensure that their operations align with sustainability objectives (Tao et al., 2023).

Enhancing environmental sustainability in pharmaceutical manufacturing requires approaches that include green manufacturing practices, comprehensive life cycle assessments, the implementation of circular economy practices, and adherence to regulatory frameworks. By prioritizing sustainability, pharmaceutical manufacturers can mitigate their environmental impacts while improving their operational performance.

2.3 Technology Adoption

The adoption of advanced technologies is critical for enhancing environmental sustainability and operational performance in pharmaceutical manufacturing. Digital transformation, characterized by the integration of digital technologies into manufacturing processes, has the potential to revolutionize the pharmaceutical industry (Ma et al., 2022). Technologies such as IoT, AI, and big data analytics enable real-time monitoring and optimization of production processes, leading to improved efficiency and reduced waste (Yang, 2023).

Automation is another critical aspect of technology adoption in pharmaceutical manufacturing. The implementation of automated systems can streamline production processes, reduce human error, and enhance product quality (Debaveye et al., 2018). For instance, automated systems can facilitate precise dosing and mixing of ingredients, ensuring consistent product quality while minimizing waste (Debaveye et al., 2018). However, the successful adoption of automation requires significant investment in technology and employee training, which can pose challenges for some organizations (Debaveye et al., 2018).

Continuous manufacturing represents a significant advancement in technology adoption within the pharmaceutical sector. This approach allows for the production of pharmaceuticals in a more efficient and sustainable manner compared to traditional batch processing (Raza, 2023). Studies have shown that continuous manufacturing can minimize waste and energy consumption compared to traditional batch processing, thereby aligning with sustainability goals (Domokos et al., 2021). However, transitioning to continuous manufacturing requires substantial investment in technology and infrastructure, which can be a barrier for some organizations (Domokos et al., 2021).

However, the successful adoption of these technologies is contingent upon several factors, including organizational readiness, management support, and stakeholder engagement. Research indicates that management support is a critical success factor in implementing Industry 4.0 technologies within the pharmaceutical sector (Debnath, 2023). Additionally, fostering a culture of innovation and collaboration among stakeholders is essential for overcoming barriers to technology adoption and achieving sustainability objectives (Yang, 2023).

The successful adoption of advanced technologies in pharmaceutical manufacturing is critical for enhancing operational performance and environmental

sustainability. Organizations must prioritize investment in technology, foster a culture of innovation, and engage stakeholders to overcome barriers to technology adoption and achieve their sustainability goals.

2.4 Theory

The theoretical framework underpinning this study is grounded in the principles of sustainable development and innovation diffusion. Sustainable development emphasizes the need to balance economic growth with environmental protection and social equity (Narula et al., 2021). In the context of pharmaceutical manufacturing, this necessitates the adoption of practices that minimize environmental impacts while enhancing operational performance. Innovation diffusion theory provides insights into how new technologies are adopted within organizations. According to this theory, the adoption of innovations is influenced by various factors, including perceived benefits, organizational readiness, and external pressures (Narula et al., 2021).

The concept of organizational readiness is critical in the context of technology adoption. Organizations that are prepared to embrace change characterized by a culture of innovation, adequate training, and resource allocation are more likely to successfully implement new technologies (Dehdasht et al., 2020). This readiness is often influenced by the existing organizational culture, which can either facilitate or hinder the adoption of sustainable practices. Management support plays a pivotal role in fostering this culture, as leaders who prioritize sustainability and innovation can drive the necessary changes within their organizations (Guan et al., 2022).

External pressures, such as regulatory requirements and market demands, also significantly influence the adoption of sustainable technologies in pharmaceutical manufacturing. Regulatory bodies increasingly impose stringent environmental standards, compelling manufacturers to adopt practices that align with sustainability goals (Zhu & Zou, 2022). Additionally, consumer awareness and demand for environmentally friendly products further incentivize pharmaceutical companies to innovate and adopt sustainable practices (Argiyantari et al., 2020).

Theoretical framework for this study integrates the principles of sustainable development and innovation diffusion theory to elucidate the dynamics of technology adoption in pharmaceutical manufacturing. By understanding the interplay between external pressures, organizational readiness, and the perceived benefits of new technologies, stakeholders can better navigate the complexities of enhancing operational performance and environmental sustainability in the pharmaceutical sector.

3 Methodology

This study employs a qualitative research methodology, utilizing a systematic literature review to synthesize existing research. The literature review process involved identifying relevant academic articles that address the intersection of technology adoption, environmental sustainability, and operational performance in the manufacturing sector. The selected literature was analyzed to identify key themes, trends, and insights relevant to the research objectives.

4 Conceptual Framework

Based on literature review, a conceptual framework is proposed to guide pharmaceutical manufacturers in their efforts to enhance sustainability and operational performance through technology adoption. The framework in Figure 1 illustrates the relationship between environmental sustainability, technology adoption, and operational performance. Environmental sustainability includes aspects like waste minimization, resource efficiency, green chemistry, circular economy practices, and regulatory adherence. These initiatives help reduce an organization's environmental impact and promote sustainable development.

Technology adoption acts as an intermediary, driven by organizational readiness and external pressures such as competition and stakeholder expectations. It facilitates the implementation of sustainable practices, leading to improved operational performance.



FIG. 1. The Relationship between Environmental Sustainability on Operational Performance with Technology Adoption as The Moderator.

Operational performance outcomes include enhanced efficiency and product quality. Efficiency focuses on optimal resource use, while product quality improvements stem from sustainable technology adoption. The framework shows that environmental sustainability drives technology adoption, which in turn enhances operational performance by improving efficiency and quality. Overall, adopting sustainable practices not only meets regulatory requirements but also provides a competitive advantage by boosting operational metrics and fostering innovation.

5 Conclusion

In conclusion, the pharmaceutical industry faces significant challenges in balancing environmental sustainability with operational performance. The adoption of advanced technologies presents a viable pathway to address these challenges, enabling companies to enhance efficiency, reduce waste, and improve product quality. However, the successful implementation of these technologies requires a supportive organizational culture, regulatory compliance, and active stakeholder engagement. This study underscores the importance of integrating sustainability into the core business strategy of pharmaceutical companies, advocating for a shift towards greener manufacturing practices. By fostering a culture of innovation and promoting cross-sector collaboration, pharmaceutical companies can achieve their sustainability goals while enhancing operational performance. Further research is needed to investigate the long-term impacts of technology adoption on sustainability outcomes in pharmaceutical manufacturing which can provide valuable insights into the effectiveness of various strategies over time.

References

Regtetg

Arden, N., Fisher, A. C., Tyner, K. M., Yu, L. X., Lee, S. L., & Kopcha, M. (2021). Industry 4.0 for Pharmaceutical Manufacturing: Preparing for the Smart Factories of the Future. International Journal of Pharmaceutics, 602, 120554. https://doi.org/10.1016/j.ijpharm.2021.120554

Argiyantari, B., Simatupang, T. M., & Basri, M. H. (2020). Pharmaceutical Supply Chain Transformation Through Application of the Lean Principle: A Literature Review. Journal of Industrial Engineering and Management, 13(3), 475. https://doi.org/10.3926/jiem.3100

Batista, L., Seuring, S., Genovese, A., Sarkis, J., & Sohal, A. (2023). Theorising circular economy and sustainable operations and supply chain management: a sustainability-dominant logic. International Journal of Operations & Production Management, 43(4), 581–594. https://doi.org/10.1108/IJOPM-12-2022-0765

D'Angelo, V., Cappa, F., & Peruffo, E. (2022). Green Manufacturing for Sustainable Development: The Positive Effects of Green Activities, Green Investments, and Non-green Products on Economic Performance. Business Strategy and the Environment, 32(4), 1900–1913. https://doi.org/10.1002/bse.3226

Debaveye, S., Torres, C. V. G., Smedt, D. De, Heirman, B., Kavanagh, S., & Dewulf, J. (2018). The Public Health Benefit and Burden of Mass Drug Administration Programs in Vietnamese Schoolchildren: Impact of Mebendazole. Plos Neglected Tropical Diseases, 12(11), e0006954. https://doi.org/10.1371/journal.pntd.0006954

Debnath, B. (2023). Assessing the Critical Success Factors for Implementing Industry 4.0 in the Pharmaceutical Industry: Implications for Supply Chain Sustainability in Emerging Economies. Plos One, 18(6), e0287149. https://doi.org/10.1371/journal.pone.0287149

Dehdasht, G., Ferwati, M. S., Zin, R. M., & Abidin, N. Z. (2020). A Hybrid Approach Using Entropy and TOPSIS to Select Key Drivers for a Successful and Sustainable Lean Construction Implementation. Plos One, 15(2), e0228746. https://doi.org/10.1371/journal.pone.0228746

Domokos, A., Nagy, B., Szilágyi, B., Marosi, G., & Nagy, Z. K. (2021). Integrated Continuous Pharmaceutical Technologies—A Review. Organic Process Research & Development, 25(4), 721–739. https://doi.org/10.1021/acs.oprd.0c00504

Emara, Y., Lehmann, A., Siegert, M.-W., & Finkbeiner, M. (2018). Modeling Pharmaceutical Emissions and Their Toxicity-related Effects in Life Cycle Assessment (LCA): A Review. *Integrated Environmental Assessment and Management*, *15*(1), 6–18. https://doi.org/10.1002/ieam.4100

Grimaldi, F., Tran, N. N., Sarafraz, M. M., Lettieri, P., Morales-Gonzalez, O. M., & Hessel, V. (2021). Life Cycle Assessment of an Enzymatic Ibuprofen Production Process with Automatic Recycling and Purification. *Acs Sustainable Chemistry & Engineering*, *9*(39), 13135–13150. https://doi.org/10.1021/acssuschemeng.1c02309

Guan, X., Chen, L., Xia, Q., & Qin, Z. S. (2022). Innovation Efficiency of Chinese Pharmaceutical Manufacturing Industry from the Perspective of Innovation Ecosystem. *Sustainability*, *14*(20), 12993. https://doi.org/10.3390/su142012993

Haji, M., Kerbache, L., Sheriff, K. M. M., & Al-Ansari, T. (2021). Critical Success Factors and Traceability Technologies for Establishing a Safe Pharmaceutical Supply Chain. *Methods and Protocols*, *4*(4), 85. https://doi.org/10.3390/mps4040085

Ingale, M. H., Tayade, M. C., Patil, Y. P., & Salunkhe, R. (2023). Data Integrity Violations in the Pharmaceutical Industry and Regulatory Measures. *International Journal of Pharmaceutical Quality Assurance*,

14(02), 416–420. https://doi.org/10.25258/ijpqa.14.2.29

Ma, J.-Y., Shi, L., & Kang, T.-W. (2022). The Effect of Digital Transformation on the Pharmaceutical Sustainable Supply Chain Performance: The Mediating Role of Information Sharing and Traceability Using Structural Equation Modeling. *Sustainability*, *15*(1), 649. https://doi.org/10.3390/su15010649

Narula, S., Puppala, H., Frederico, G. F., Dwivedy, M., Prakash, S., & Talwar, V. (2021). Applicability of Industry 4.0 Technologies in the Adoption of Global Reporting Initiative Standards for Achieving Sustainability. *Journal of Cleaner Production*, *305*, 127141. https://doi.org/10.1016/j.jclepro.2021.127141

Pesqueira, A. M., & Sousa, M. J. (2020). *Pharmaceuticals and Life Sciences*. 237–254. https://doi.org/10.4018/978-1-5225-9993-7.ch014

Raza, S. (2023). The Dynamics of Innovation on Firm Performance: Empirical Analysis of Pharmaceutical Manufacturing Firms in Sindh Pakistan. *Pakistan Journal of Humanities and Social Sciences*, *11*(2). https://doi.org/10.52131/pjhss.2023.1102.0424

Riikonen, S., Timonen, J., & Sikanen, T. (2024). Environmental considerations along the life cycle of pharmaceuticals: Interview study on views regarding environmental challenges, concerns, strategies, and prospects within the pharmaceutical industry. *European Journal of Pharmaceutical Sciences*, *196*, 106743. https://doi.org/10.1016/j.ejps.2024.106743

Tao, Y., Zhu, S., Smith, J., Lakhani, N., & You, F. (2023). Environmental Sustainability of the Globalized Pharmaceutical Supply Chains: The Case of Tenofovir Disoproxil Fumarate. *Acs Sustainable Chemistry & Engineering*, *11*(17), 6510–6522. https://doi.org/10.1021/acssuschemeng.2c06518

Yang, P. (2023). Moving Toward Sustainable Development: The Influence of Digital Transformation on Corporate ESG Performance. *Kybernetes*, *53*(2), 669–687. https://doi.org/10.1108/k-03-2023-0521

Younnes, D. (2023). The Impact of Lean Manufacturing Practices on Green Sustainability: The Case of Abdulghani Company. *European Journal of Business Management and Research*, *8*(3), 62–67. https://doi.org/10.24018/ejbmr.2023.8.3.1905

Zhu, W., & Zou, J. (2022). The Impact of Green Technology Innovation of New Energy Companies on Earnings Sustainability in China—Based on the Regulatory Effect of Green Finance Development. *American Journal of Industrial and Business Management*, *12*(08), 1348–1362. https://doi.org/10.4236/ajibm.2022.1280, 73